These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 33082482)
1. Reduced EGFR and increased miR-221 is associated with increased resistance to temozolomide and radiotherapy in glioblastoma. Areeb Z; Stuart SF; West AJ; Gomez J; Nguyen HPT; Paradiso L; Zulkifli A; Jones J; Kaye AH; Morokoff AP; Luwor RB Sci Rep; 2020 Oct; 10(1):17768. PubMed ID: 33082482 [TBL] [Abstract][Full Text] [Related]
2. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935 [TBL] [Abstract][Full Text] [Related]
3. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma. Shang C; Tang W; Pan C; Hu X; Hong Y Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide. Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977 [TBL] [Abstract][Full Text] [Related]
6. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849 [TBL] [Abstract][Full Text] [Related]
7. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Stojcheva N; Schechtmann G; Sass S; Roth P; Florea AM; Stefanski A; Stühler K; Wolter M; Müller NS; Theis FJ; Weller M; Reifenberger G; Happold C Oncotarget; 2016 Mar; 7(11):12937-50. PubMed ID: 26887050 [TBL] [Abstract][Full Text] [Related]
9. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
10. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme. Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285 [TBL] [Abstract][Full Text] [Related]
11. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status. Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314 [TBL] [Abstract][Full Text] [Related]
12. miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. Wei J; Qi X; Zhan Q; Zhou D; Yan Q; Wang Y; Mo L; Wan Y; Xie D; Xie J; Yang S Biomed Pharmacother; 2015 Apr; 71():112-8. PubMed ID: 25960225 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma. Tian T; Mingyi M; Qiu X; Qiu Y Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996 [TBL] [Abstract][Full Text] [Related]
14. MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1. Jia B; Liu W; Gu J; Wang J; Lv W; Zhang W; Hao Q; Pang Z; Mu N; Zhang W; Guo Q Exp Cell Res; 2019 Feb; 375(1):73-81. PubMed ID: 30586549 [TBL] [Abstract][Full Text] [Related]
15. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000 [TBL] [Abstract][Full Text] [Related]
16. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-566 activates EGFR signaling and its inhibition sensitizes glioblastoma cells to nimotuzumab. Zhang KL; Zhou X; Han L; Chen LY; Chen LC; Shi ZD; Yang M; Ren Y; Yang JX; Frank TS; Zhang CB; Zhang JX; Pu PY; Zhang JN; Jiang T; Wagner EJ; Li M; Kang CS Mol Cancer; 2014 Mar; 13():63. PubMed ID: 24650032 [TBL] [Abstract][Full Text] [Related]
18. Lnc-TALC promotes O Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733 [TBL] [Abstract][Full Text] [Related]
19. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397 [TBL] [Abstract][Full Text] [Related]
20. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]